1. Academic Validation
  2. Self-Illuminating Nanoagonist Simultaneously Induces Dual Cell Death Pathways via Death Receptor Clustering for Cancer Therapy

Self-Illuminating Nanoagonist Simultaneously Induces Dual Cell Death Pathways via Death Receptor Clustering for Cancer Therapy

  • ACS Nano. 2024 Jul 2;18(26):17119-17134. doi: 10.1021/acsnano.4c03767.
Yuchan You 1 Luwen Zhu 1 Yanling Song 1 Jiahao Hu 1 Minjiang Chen 2 Jucong Zhang 1 Xinyi Xu 1 Xiajie Huang 1 Xiaochuan Wu 1 Jingyi Lu 1 Xiangmin Tong 3 Jian-Song Ji 2 Yong-Zhong Du 1 4
Affiliations

Affiliations

  • 1 College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou 310058, P. R. China.
  • 2 Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Lishui Central Hospital and Fifth Affiliated Hospital of Wenzhou Medical College, 289 Kuocang Road, Lishui 323000, P. R. China.
  • 3 Department of Hematology, the Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou 310006, P. R. China.
  • 4 Innovation Center of Transformational Pharmacy, Jinhua Institute of Zhejiang University, Jinhua 321299, P. R. China.
Abstract

Inducing Death Receptor 5 (DR5) clustering holds particular promise in tumor-specific therapeutics because it could trigger an apoptotic cascade in cancerous cells. Herein, we present a tumor microenvironment H2O2-responsive self-illuminating nanoagonist, which could induce dual tumor cell death pathways through enhancing DR5 clustering. By conjugating DR5 ligand Peptides onto the surfaces of self-illuminating nanoparticles with cross-linking capacity, this strategy not only provides scaffolds for ligands to bind receptors but also cross-links them through photo-cross-linking. This strategy allows for efficient activation of DR5 downstream signaling, initiating the extrinsic Apoptosis pathway and immunogenic cell death of tumor cells, and contributes to improved tumor-specific immune responses, resulting in enhanced antitumor efficacy and minimized systemic adverse effects.

Keywords

cancer immunotherapy; death receptor; photo-cross-linking; receptor clustering; self-illuminating nanoparticle.

Figures
Products